Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Oct 2020
Historique:
pubmed: 26 6 2020
medline: 23 2 2021
entrez: 26 6 2020
Statut: ppublish

Résumé

Immune checkpoint inhibitors can affect any organ, including the salivary glands. A case of Sjögren's syndrome (SjS) induced by nivolumab for the treatment of gastric cancer is herein presented. Nivolumab treatment caused marked tumor shrinkage, but xerostomia developed after two cycles. It took 3 months after symptom onset to confirm the diagnosis of SjS. Prednisolone and pilocarpine hydrochloride did not relieve the symptoms. SjS is a relatively rare immune-related adverse event that might sometimes be overlooked. Since SjS can severely impair a patient's quality of life, oncologists should not miss any signs of salivary gland hypofunction and cooperate with specialists for SjS.

Identifiants

pubmed: 32581160
doi: 10.2169/internalmedicine.4701-20
pmc: PMC7662059
doi:

Substances chimiques

Antineoplastic Agents 0
Pilocarpine 01MI4Q9DI3
Nivolumab 31YO63LBSN
Prednisolone 9PHQ9Y1OLM

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2499-2504

Références

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):114-122
pubmed: 31464670
Ann Rheum Dis. 2017 Jan;76(1):43-50
pubmed: 27307501
RMD Open. 2017 Mar 20;3(1):e000412
pubmed: 28405474
Oncologist. 2020 Feb;25(2):e391-e395
pubmed: 32043780
Respirol Case Rep. 2018 Apr 15;6(5):e00322
pubmed: 29686875
Eur J Cancer. 2017 Sep;82:34-44
pubmed: 28646772
Ann Oncol. 2017 Dec 1;28(12):3108
pubmed: 29045656
Oncologist. 2019 Sep;24(9):1259-1269
pubmed: 30996010
Autoimmun Rev. 2018 Oct;17(10):1040-1045
pubmed: 30103042
Support Care Cancer. 2010 Aug;18(8):1039-60
pubmed: 20237805
J Autoimmun. 2010 Jun;34(4):400-7
pubmed: 19889514
Mod Rheumatol. 2004 Dec;14(6):425-34
pubmed: 24387718
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921

Auteurs

Tetsuo Higashi (T)

Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan.

Hideaki Miyamoto (H)

Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan.

Ryoji Yoshida (R)

Department of Oral and Maxillofacial Surgery, Kumamoto University, Japan.

Yoki Furuta (Y)

Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan.

Katsuya Nagaoka (K)

Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan.

Hideaki Naoe (H)

Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan.

Hisaki Naito (H)

Department of Oral and Maxillofacial Surgery, Kumamoto University, Japan.

Hideki Nakayama (H)

Department of Oral and Maxillofacial Surgery, Kumamoto University, Japan.

Motohiko Tanaka (M)

Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH